GenomONE™ -Neo EX HVJ-E 1 vial Transfection Reagents - Cosmo Bio Co.,Ltd.

Antibodies

>

GenomONE™ -Neo EX HVJ-E 1 vial Transfection Reagents

Catalog No.: ISK-GN-001-EX
Size: 1SET
Price: ¥25000
$334
catalog info: Catalog 2012-p208
Storage: 4C
@
Purpose: GenomONE™ -Neo EX is a non-viral reagent for transfection, Unique, efficient transfection of siRNA, DNA oligonucleotides, proteins. Low toxicity with primary cells. Protocols for in vivo transfection.
component: Freeze-dried HVJ-E (inactivated HVJ) - 1 vial (0.26 mL /via)
Reagent A (enhancer for incorporation) - 1 vial (0.5 mL/vial)
Reagent B (reagent for incorporation) - 1 vial (0.3 mL/vial)
Reagent C (enhancer for introduction) - 1 vial (1.0 mL/vial)
Buffer (for suspension and dilution) - 1 vial (6.5 mL/vial)

Other:

 Background 
HVJ (hemagglutinating virus of Japan) Envelope VECTOR KIT is a tool for transfection of molecules (plasmid DNAs, siRNAs, oligonucleotides, proteins, antibodies etc.) into cells and animal tissue by means of membrane fusion. The HVJ envelope, carrying the molecule to be transfected, is composed of a completely inactivated and purified HVJ (Sendai virus) while preserving the cell membrane-fusing capability of the envelope.
GenomONE provides ready-to-use kits containing the HVJ envelope and auxiliary reagents (incorporation enhancer, incorporation reagent, introduction enhancer, buffer).
 Principle 
What is HVJ Envelope (HVJ-E)
HVJ Envelope is a purified product prepared through complete inactivation of Sendai virus (HVJ#). It is a vesicle in which only the cell membrane-fusing capability of the envelope protein of Sendai virus is retained.
It is known that the HN protein in the tunica externa of the Sendai virus recognizes the receptor (possessing sialic acid atthe terminal of sugar chain) on the cell membrane and adsorbs it, leading to the induction of membrane fusion mediated by F protein (another component of the envelope). The genomic RNA of the Sendai virus contained in HVJ-E has been inactivated completely and has neither infective nor proliferative potentials in humans or experimental animals. HVJ-E can be used safely at ordinary laboratories, without requiring any special operations or facilities.
#HVJ: Hemagglutinating Virus of Japan.
Conventionalnon-viral transfection tools, including cationic lipids, are incorporated into cells through endocytosis which results in degradation of the transferred DNA by lysosomes. On the other hand, HVJ Envelope VECTOR resists degradation by lysosomes, makingit easy to transfer the specified DNA. Therefore, HVJ Envelope VECTOR yields highly efficient gene expression. Sialic acid receptors, which are needed to trigger binding with HN protein, exist in almost all animal cells. Thus, HVJ EnvelopeVECTOR isuseful for a wide range of targets.
 Feature and advantages 
1. Wide usability - GenomONE™ HVJ Envelope VECTOR KIT is a highly flexible tool for transfecting a wide variety of molecules (plasmid DNAs, siRNAs, oligonucleotides, proteins,antibodiesetc.) into cultured cells (adherent and non-adherent) and tissue. GenomONE is useful for transfecting sensitive primary cells and is further distinguished by its ability to deliver contents into live animals. Many literature citations areavailable foreach GenomONE-Neo application.
2. Safety - Unlike cationic lipids, GenomONE-Neo delivers the molecule of interest into cells via membrane fusion, not by endocytosis where cargo may be degraded by lysosomal enzymes. Since GenomeONE™ -Neo is apurified HVJ (Sendai virus) product, prepared from virus particles completely inactivated for infectious ability and proliferative potential it is completely safe to use without special precautions.
3. Easy - GenomONE™ provides ready-to-use kitscontaining the HVJ envelope and required auxiliary reagents (incorporation enhancer, incorporation reagent, introduction enhancer, and buffer). Suggested protocols for all major applications are included.
 Application 
1. siRNA transfection
in vitro:
Primary T cell (Human peripheral blood)
Primary cardiac myocyte (Rat cardiac myocyte)
Differentiated C2C12 (Mouse myoblast)
monkey ES cells
Min6 (Mouse pancreatic β cell)
U937 (Human myelomonocytic cell)
in vivo:
Intradermally transplanted human cervix cancer /HeLa (SCID mouse)
Submandibular gland (rat)
2. Protein delivery
in vivo:
Primary macrophage (C3H mouse peritoneal resident)
Swiss 3T3 cell (Mouse embryonic fibroblasts)
in vivo:
Nucleus tractus solitarius (Rat brain)
3. Oligo DNA transfection
in vitro:
Primary HDMECs (Human dermal microvascular endothelial cell)
Primary CD34+ cell (Human blood)
in vivo:
Uterus (Mouse)
Skin, ear lobe(Mouse)
Lung (Mouse)
4. Plasmid DNA transfection
in vivo:
Uterus(Mouse)
Palatal periodontal tissue (Rat)
Myocardium (Rat heart)
Lung (neonatal porcine)
Subcutaneously transplanted human colon cancer /LoVo (nude mouse)



 IMAGE1





 IMAGE2





 IMAGE3





Reference:

in vitro
Antisense/decoy ODN transfection (in vitro)
•  S. Akagi et al., J. Am. Soc. Nephrol., 15, 3215-3224 (2004).
•  S. F Feigl et al., J. Clin. Invest.,115, 3057-3071 (2005).
•  S. F Feigl et al., Nature Med., 12,99-106 (2006).
•  Y. Miyazaki et al., Am. J. Pathol.,169, 697-707 (2006).
•  Y. Kubota et al., J. Immunol., 178, 2923-2931 (2007).
•  G. Son et al., Am J Physiol Gastrointest Liver Physiol., 293, 631-639 (2007).
•  KF.Takahashi et al., BMC Dev Biol. 10(1), 115. (2010).
•  Y. Nakamura et al., Int. Arch. Allergy Immunol.,155, 129-140 (2011).
•  Y. F. Ookuma et al., Histochem. Cell Biol., 139(2) 355-370 (2013).
siRNA transfection /miRNAtransfection (in vitro)
•  Y. Itoh et al., Nature, 422(13), 173-176 (2003).
•  T. Ishii et al., J. Immunol., 170(1), 3653-3661 (2003).
•  C. Kojima et al., EMBO J., 23, 4413-4422 (2004).
•  K. Ohnuma et al.,Proc. Natl. Acad. Sci. USA, 101(39),14186-14191 (2004).
•  A. Watanabe et al., J. Mol. Cell. Cardiol., 37(3), 691-698 (2004).
•  M. Asada et al., Mol. Cell. Biol., 24(18), 8236-8243 (2004).
•  R. Kuribara et al., Mol.Cell. Biol., 24(14), 6172-6183 (2004).
•  T. Matsumoto et al., EMBO J., 24, 2342-2353 (2005).
•  T. Takada et al., Biochem. Biophys. Res. Commun., 331(4),1039-1044 (2005).
•  K. Ohnuma et al., Mol. Cell. Biol., 25,7743-7757(2005).
•  S. Sangkhathat et al., Int. J. Oncology, 28, 715-722 (2006).
•  S. F Feigl et al., Nature Med., 12, 99-106 (2006).
•  D. D Feng et al., Endocrinology, 147, 674-682 (2006).
•  K. Ohnuma et al., J. Biol. Chem., 282(13), 10117-10131 (2007).
•  Y. Nakamichi et al., J. Immunol., 178, 192-200 (2007).
•  A. Masuda et al., J. Immunol., 178, 360-368 (2007).
•  H. Iguchi et al., J. Biol. Chem., 282(26), 19052-19061(2007).
•  Y. Kubota et al., J. Immunol., 178, 2923-2931 (2007).
•  M. Shimada et al., Mol. Endocrinol., 21, 2487-2502 (2007).
•  Y. Yamashita et al., Endocrinology, 148, 6164-6175 (2007).
•  E. Saito et al., J. Atheroscler.Thromb., 14, 317-324 (2007).
•  Y. Tsuchiya et al., Free Radical Biology and Medicine, 43(12),1604-1615 (2007).
•  Y. Nimura et al., Int. J. Oncol., 30(6), 1477-1484 (2007).
•  Y. Sawa et al., J. Histochem. Cytochem., 56, 97-109 (2008).
•  T. Saito et al., British J. Cancer, 98, 345-355 (2008).
•  M. Shimada et al., Development, 135, 2001-2011 (2008).
•  H-Y Fan et al., Development, 135, 2127-2137 (2008).
•  H. Mukaide et al., Cancer Invest., 26,385-390 (2008).
•  J J. Conkright et al., Am. J. Respir. Cell Mol. Biol., 42, 181-189(2010).
•  J P. Bridges et al., J. Clin. Invest., 120(5), 1736-1748 (2010).
•  A. Watanabe et al., Cardiovasc.Res., 90(1), 57-67 (2011).
•  F. Jafarifar et al., EMBO J., 30, 1324-1334 (2011).
•  S. Koyanagi et al., J. Biol. Chem., 286 32416-32423 (2011).
•  B. Kosmider et al., PLoS One. 6(12), e26059 (2011).
•  Y. Kobayashiet al., PLoS One. 6(12), e27627 (2011).
•  S. M. Tietz et al., J. Biomol. Tech.,12, 2302-2305 (2012).
•  B. Kosmider et al., Respir. Res., 13(1), 43, (2012).
•  Y. Kobayashi et al., Pulm. Pharmacol. Ther., 25(3),201-207 (2012).
•  T. Saito et al., Circulation, 127(1) 104-114 (2013).
•  A. Funayama et al., Cardiovasc. Res., S99(4) 657-664 (2013).
•  M. Fujiya et al., Oncogene 2013 (in press)
•  Y. Tanaka et al., BMC Cancer, 14(1), 27 (2014).
Protein/Peptide transfection (in vitro)
•  S. Yuki et al., Eur. J. Biochem., 271(17), 3567-3572 (2004).
•  Y. Kubota et al., Int. J. Radiat. Biol., 81(6), 459-472 (2005).
•  T. Matsumoto et al., EMBO J., 24, 2342-2353 (2005).
•  K. Kitadokoro et al., Proc. Natl. Acad. Sci. USA, 104(12), 5139-5144 (2007).
•  S. Kamitani et al., J. Biol. Chem., 285(33), 25467-25475 (2010).
•  S. Matsuda et al., PLoS Pathog., 8(7),e1002803 (2012).
•  E. Hernandez-Cuellar et al., J. Immunol., 189(11), 5113-5117(2012).
•  H. Hara et al., Nature Immunol., 14, 1247-1255 (2013).
Antibody delivery into living cells (in vitro)
•  Y. Kondo et al., J. Immunol. Methods, 332, 10-17 (2008).
•  S. Balasubramanian et al., PLoS One., 5(7), e11470 (2010).
Bioimaging (in vitro , ex vivo)
•  K. Toyoda et al., Neuroreport, 15 (4), 589-593 (2004).
•  JA Flexman et al., ConfProc IEEE Eng Med Biol Soc. 7, 5246-5249 (2004).
•  S. Miyoshi et al., Mol. Imaging Biol.,7(4), 286-295 (2005).
•  Y. Song et al., Histol. Histopathol., 21(7), 705-711 (2006).
•  K.Takata et al., FEBS Letters, 581,475-478(2007).
•  N.Takehara et al., J. Am. Coll. Cardiol., 52(23), 1858-1865 (2008).
•  T.Takimoto et al., Chem. Mater., 22 (11) 3462-3471 (2010).
•  JA. Flexman et al., Mol. Imaging Biol.,13(1), 104-111 (2011).
•  M. Kawamura et al., Circulation, 128, S87-594 (2013).
Plasmid DNA transfection (in vitro, ex vivo)
•  T. Watanabe et al., Nature Immunol., 5, 800-808 (2004).
•  Y. Ikeda et al., Hypertens. Res., 27(2), 119-228 (2004).
•  J. Eguchiet al., Biochem. J., 387, 343-353 (2005).
•  J. Ohishi et al., J. Control. Release, 110(2), 431-436 (2006).
•  T. Nishikawa et al., Hum. Gene Ther., 17(4), 470-475 (2006).
•  Y. Nakamichi et al., J. Immunol.,178, 192-200 (2007).
•  T. Shimamura et al., J. Immunol., 181, 4656-4665 (2008).
•  T. Akaike et al., J. Biol. Chem., 284(36), 24025-24034 (2009).
•  M. Sato et al., J. Biol. Chem.,284(45), 31431-31440 (2009).
•  J.L Espinoza et al., PLoS One,7(12) e51306 (2012).
•  R. Zhou et al., J. Biol. Chem., 288, 5389-5397 (2013).
•  Y. Kitamura et al., J. Biol. Chem., 289, 2788-2800 (2014).
◊  Y. Kaneda et al., Mol. Ther.,6(2), 219-226 (2002).
◊  Y. Kaneda Curr. Drug Targets, 4(8), 599-602 (2003).
◊  H. Kotani et al., Curr. Gene Ther., 4(2), 183-194 (2004).
◊  Y. Kaneda et al., Adv. Genet., 53, 307-332 (2005).
◊  Y. Kaneda et al., CancerSci., 97(5),348-354 (2006).
◊  Y. Kaneda, Expert Opinion Drug Deliv., 5(2), 221-233 (2008).
◊  Q. Zhang et al., Biochem Biophys Res Commun, 373, 345-349 (2008).
◊  P E.Lund et al., Pharm. Res., 27(3), 400-420 (2010).
◊  Y. Kondoet al., Curr. Protoc. Immunol., 2, Unit 2.16.1-12 (2010).
◊  Y. Kondo et al., Curr. Protoc. Immunol.,10, Unit 10.17D.1-9 (2010).
◊  T. Amatsubo et al., Magn. Reson. Med. Sci.,9(3) 95-99 (2010)
◊  Y. Kaneda, Expert. Opin. Drug Deliv.,(9), 1079-1093 (2010)
◊  A. Kitani et al., Curr. Protoc. Immunol., 10, Unit 10.17E.1-9 (2010).
◊  Y. Kaneda, BMB Rep., 43(12) 773-780 (2010).
◊  Y. Kaneda, Adv. Drug Deliv. Rev., 64(8), 730-738 (2012).
◊  F. Kato et al., J. Genet.Syndr. Gene Ther., 4, 178 (2013)
in vivo
Decoy ODN transfection (in vivo)
•  K. Sumi et al., Gene Ther.,11(24), 1763-1771 (2004).
•  N. Matsuda et al., Mol. Pharmacol., 67, 1018-1025 (2005).
•  S. F Feigl et al.,J. Clin. Invest.,115, 3057-3071 (2005).
•  H. Nakamura et al., FEBS Lett., 580(11), 2717-2722 (2006).
•  N. Matsuda et al., J. Pharmacol. Exp.Ther., 332(3), 730-737 (2010).
•  T. Watanabe et al., J. Clin. Invest..,120(5), 1645-1662 (2010).
•  T. Kimura et al., Indian J. Physiol. Pharmacol., 54(5),27-32 (2010).
•  Y. Oishi et al., Am. J. Physiol. Lung Cell Mol. Physiol., 303(2), 130-140 (2012).
siRNA transfection / miRNA transfection (in vivo)
•  M. Ito et al., J.Gene Med., 7(8), 1044-1052 (2005).
•  S. F Feigl et al., Nature Med.,12, 99-106 (2006).
•  K. Ishibashi et al., J. Dent. Res., 85(12), 1101-1105 (2006).
•  S. F Feigl et al., J. Immunol., 178, 5859 - 5870 (2007).
•  Y. Nimura et al., Int. J. Oncol., 30(6), 1477-1484 (2007).
•  T. Watanabe et al., J. Clin. Invest., 118(2), 545-559 (2008).
•  K. Ishibashi et al., Am J Physiol Regulatory Integrative CompPhysiol., 294, 1729-1736 (2008).
•  Y. Doi et al., Proc. Natl. Acad. Sci. USA, 105(24), 8381-8386 (2008).
•  H. Kato et al., J. Exp. Med., 205, 1601-1610 (2008).
•  K. Morita et al., J. Pharmacol. Exp. Ther., 326, 633-645 (2008).
•  M. Boirivant et al., Gastroenterology, 135(5), 1612-1623 (2008).
•  K. Morita et al., Pain,138(3), 525-536 (2008).
•  M. Matsuda et al., Gene Ther.,16(12), 1465-1476 (2009).
•  N. Matsuda et al., J. Pharmacol. Exp.Ther., 332(3), 730-737 (2010).
•  T. Watanabe et al., J. Clin. Invest., 120(5), 1645-1662 (2010).
•  T.Takahashi et al., Pain, 150(1), 183-191 (2010).
•  E.Tskitishvili et al., Am. J. Obstet. Gynecol., 203(4),364.e6-e12 (2010).
•  T. Fujioka et al., J. Pharmacol, Sci., 113(4), 353-361(2010).
•  L. Chen et al., Circulation, 122, 910-919 (2010).
•  R. Naono-Nakayama et al., Eur. J. Pharmacol., 670, 448-457(2011).
•  Y. Mitsuishi et al., Cancer Cell, 22(1), 66-79 (2012).
•  J. Jin et al., Am. J. Transl. Res., 4(3) 302-315 (2012).
•  E. Kiyohara et al., Gene Ther., 19(7), 734-741(2012).
•  N. Motoyama et al., Eur. J. Pain, 17(8), 1156-1167 (2013).
•  T. Kitayama et al., Molecular Pain, 9, 23 (2013).
•  M. Fujiya et al., Oncogene, 2013 (in press)
•  SM. Brunner et al., Transplant Res., 2(1) 16 (2013).
•  K. Morita et al., PLoS One. 9(3) e91746 (2014).
Protein (antibody) transfection (in vivo)
•  K. Owada-Makabe et al., Neurosci. Lett., 378(1), 18-21 (2005).
•  E. Yasuoka et al., J. Mol. Med., 85(3), 279-288 (2007).
•  K. Shintani-Ishida et al., Biochim.Biophys.Acta.,1812(7), 743-751 (2011).
•  K. Shintani-Ishida et al., J.Mol. Cell.Cardiol., 53(2), 233-239(2012).
Plasmid DNA transfection (in vivo)
•  H. Nakamura et al., Mol. Hum. Reprod., 9(10), 603-609 (2003).
•  K. Oshima et al., FASEB J., 18(1), 212-214 (2003).
•  H. Kanzaki et al., J. Dent. Res., 83(12), 920-925 (2004).
•  M. Ono et al., Circulation,110, 2896-2902 (2004).
•  H. Nakamura et al., Biochem. Biophys. Res. Commun., 321(4), 886-892 (2004).
•  M. Takeno et al., Clin. Exp. Allergy, 34(6), 965-970 (2004).
•  T. Itani et al., Int.J. Mol. Med.,16, 821-825(2005).
•  T. Matsuoka et al., Diabetes, 54, 2882-2890 (2005).
•  M. Ono etal., J. Thorac. Cardiovasc. Surg.,129, 740-745 (2005).
•  N. Shigemura et al., Circulation, 111, 1407-1414 (2005).
•  N. Shigemura et al., Am. J. Respir. Crit. Care Med.,171, 1237-1245 (2005).
•  H. Futamatsu et al., Circ. Res.,96, 823-830 (2005).
•  Y. D. Kim et al., Gene Ther., 13(3), 216-224 (2006).
•  H. Kanzaki et al., Gene Ther., 13(8), 678-685 (2006).
•  H. Suzuki et al., Cancer Biol. Ther., 5(11), 1487-1491 (2006).
•  Y. Zhang et al., J. Am. Soc. Nephrol., 17, 1090-1101 (2006).
•  M. Ieda et al., Circulation, 114, 2351-2363(2006).
•  T. Hamada et al., Am. J. Pathol., 171,872-881 (2007).
•  T. Watanabe et al., J. Clin. Invest., 118(2),545-559 (2008).
•  Y. Mitani et al., J. Thorac. Cardiovasc. Surg.,136(1), 142-149 (2008).
•  H. Matsubara et al., Clin Orthop Relat Res. 466(12), 2962-2672 (2008).
•  M. Okada et al., Vaccine, 27, 3267-3270 (2009).
•  T.Fujita et al., Cancer Res., 69(12), 5142-5150 (2009).
•  H. Kidoya et al., Blood. 115(15), 3166-3174 (2010).
•  T. Okabayashi et al., PLoS One, 5(9), e13034 (2010).
•  M. Tomomura et al., In Vivo, 25, 157-163(2011).
•  M. Okada et al., Clin. Dev. Immunol.,549281 (2011)
•  M. S. Salker et al., Nature Med., 17, 1509-1513 (2011).
•  N. Zhao et al., Am.J.Orthod Dentofacial Orthop.,141, 30-40 (2012).
•  N. Zhao et al.,Orthod. Craniofac. Res.,15(1),10-20, (2012).
•  N. Zhao et al., Orthod. Craniofac. Res.,15(1),10-20, (2012).
•  H. Kanzaki et al., J. Biol. Chem., 288(32) 23009-23020(2013).
•  K. Hasegawa et al., NatureMedicine,19, 1496-1504 (2013).
•  T. Watanabe et al., Mucosal Immunology (in press) 2014
Bioimaging (in vivo)
•  J A Flexman et al., IEEE Trans Nanobioscience, 7(3), 223-232(2008).
◊  Y. Kaneda et al., Mol. Ther.,6(2), 219-226 (2002).
◊  Y. Kaneda, Curr. Drug Targets, 4(8), 599-602 (2003).
◊  H. Kotani et al., Curr. Gene Ther., 4(2), 183-194 (2004).
◊  Y. Kaneda et al., Adv. Genet., 53, 307-332 (2005).
◊  Y. Kaneda et al., Cancer Sci., 97(5), 348-354 (2006).
◊  Y. Kaneda, Expert Opinion Drug Deliv., 5(2), 221-233 (2008).
◊  Q. Zhang et al., Biochem Biophys Res Commun, 373, 345-349 (2008).
◊  P E. Lund et al., Pharm. Res., 27(3), 400-420 (2010).
◊  Y. Kondo et al.,Curr. Protoc. Immunol., 2, Unit 2.16.1-12 (2010).
◊  Y. Kondo et al., Curr. Protoc. Immunol.,10, Unit 10.17D.1-9 (2010).
◊  T. Amatsubo et al., Magn. Reson. Med. Sci.,9(3) 95-99 (2010)
◊  Y. Kaneda, Expert. Opin. Drug Deliv., (9), 1079-1093 (2010)
◊  A. Kitani et al., Curr. Protoc. Immunol., 10, Unit 10.17E.1-9 (2010).
◊  Y. Kaneda, BMB Rep., 43(12) 773-780 (2010).
◊  Y. Kaneda, Adv. Drug Deliv. Rev., 64(8), 730-738 (2012).
◊  F. Kato et al., J. Genet. Syndr. Gene Ther., 4, 178 (2013)
 
>